Presence of receptors for bombesin/gastrin-releasing peptide and mRNA for three receptor subtypes in human prostate cancers

Baodong Sun, Gabor Halmos, Andrew V Schally, Xiaofei Wang, Miriam Martinez

Research output: Contribution to journalArticle

151 Citations (Scopus)

Abstract

BACKGROUND. Bombesin-like peptides can function as autocrine or paracrine growth factors and stimulate the growth of some cancer cells, including human prostate cancer. Three bombesin receptor subtypes, termed gastrin-releasing peptide receptor (GRPR), neuromedin B receptor (NMBR), and bombesin receptor subtype 3 (BRS-3), have been identified in rodents and humans. METHODS. We investigated the presence and characteristics of the functional receptors for bombesin/GRP in human prostate adenocarcinoma specimens by radio-receptor assay and the mRNA expression of the three bombesin receptor subtypes by RT-PCR. RESULTS. Of the 80 specimens of primary prostate cancer examined by receptor binding assays, 50 (~63%) showed high- affinity, low-capacity binding sites for bombesin/GRP, and 12 of these 50 receptor-positive specimens also showed a second binding site. Of the 22 prostate cancer specimens analyzed by RT-PCR, 20 (91%) expressed GRPR mRNA, 3 (14%) showed NMBR mRNA, and 2 (~9%) revealed BRS-3 mRNA. No correlation was observed between receptor expression and patients' age or pathological data. CONCLUSIONS. The detection of a wide distribution of bombesin/GRP receptors in human prostate carcinomas supports the view that they may be involved in modulation of tumor progression and suggests that approaches based on binding of bombesin receptor antagonists or new targeted cytotoxic bombesin analogs to prostate cancers could be considered for the therapy. (C) 2000 Wiley-Liss, Inc.

Original languageEnglish
Pages (from-to)295-303
Number of pages9
JournalProstate
Volume42
Issue number4
DOIs
StatePublished - Mar 1 2000
Externally publishedYes

Fingerprint

Bombesin Receptors
Prostatic Neoplasms
Messenger RNA
Bombesin
Prostate
Binding Sites
Polymerase Chain Reaction
Radio
Rodentia
Neoplasms
Intercellular Signaling Peptides and Proteins
Adenocarcinoma
Carcinoma

Keywords

  • Bombesin receptor
  • Cancer therapy
  • Peptide analogs
  • Prostate cancer
  • Receptor binding assay
  • RT-PCR

ASJC Scopus subject areas

  • Urology

Cite this

Presence of receptors for bombesin/gastrin-releasing peptide and mRNA for three receptor subtypes in human prostate cancers. / Sun, Baodong; Halmos, Gabor; Schally, Andrew V; Wang, Xiaofei; Martinez, Miriam.

In: Prostate, Vol. 42, No. 4, 01.03.2000, p. 295-303.

Research output: Contribution to journalArticle

Sun, Baodong ; Halmos, Gabor ; Schally, Andrew V ; Wang, Xiaofei ; Martinez, Miriam. / Presence of receptors for bombesin/gastrin-releasing peptide and mRNA for three receptor subtypes in human prostate cancers. In: Prostate. 2000 ; Vol. 42, No. 4. pp. 295-303.
@article{d362231b17c3438db109e13dd2a8f36c,
title = "Presence of receptors for bombesin/gastrin-releasing peptide and mRNA for three receptor subtypes in human prostate cancers",
abstract = "BACKGROUND. Bombesin-like peptides can function as autocrine or paracrine growth factors and stimulate the growth of some cancer cells, including human prostate cancer. Three bombesin receptor subtypes, termed gastrin-releasing peptide receptor (GRPR), neuromedin B receptor (NMBR), and bombesin receptor subtype 3 (BRS-3), have been identified in rodents and humans. METHODS. We investigated the presence and characteristics of the functional receptors for bombesin/GRP in human prostate adenocarcinoma specimens by radio-receptor assay and the mRNA expression of the three bombesin receptor subtypes by RT-PCR. RESULTS. Of the 80 specimens of primary prostate cancer examined by receptor binding assays, 50 (~63{\%}) showed high- affinity, low-capacity binding sites for bombesin/GRP, and 12 of these 50 receptor-positive specimens also showed a second binding site. Of the 22 prostate cancer specimens analyzed by RT-PCR, 20 (91{\%}) expressed GRPR mRNA, 3 (14{\%}) showed NMBR mRNA, and 2 (~9{\%}) revealed BRS-3 mRNA. No correlation was observed between receptor expression and patients' age or pathological data. CONCLUSIONS. The detection of a wide distribution of bombesin/GRP receptors in human prostate carcinomas supports the view that they may be involved in modulation of tumor progression and suggests that approaches based on binding of bombesin receptor antagonists or new targeted cytotoxic bombesin analogs to prostate cancers could be considered for the therapy. (C) 2000 Wiley-Liss, Inc.",
keywords = "Bombesin receptor, Cancer therapy, Peptide analogs, Prostate cancer, Receptor binding assay, RT-PCR",
author = "Baodong Sun and Gabor Halmos and Schally, {Andrew V} and Xiaofei Wang and Miriam Martinez",
year = "2000",
month = "3",
day = "1",
doi = "10.1002/(SICI)1097-0045(20000301)42:4<295::AID-PROS7>3.0.CO;2-B",
language = "English",
volume = "42",
pages = "295--303",
journal = "Prostate",
issn = "0270-4137",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Presence of receptors for bombesin/gastrin-releasing peptide and mRNA for three receptor subtypes in human prostate cancers

AU - Sun, Baodong

AU - Halmos, Gabor

AU - Schally, Andrew V

AU - Wang, Xiaofei

AU - Martinez, Miriam

PY - 2000/3/1

Y1 - 2000/3/1

N2 - BACKGROUND. Bombesin-like peptides can function as autocrine or paracrine growth factors and stimulate the growth of some cancer cells, including human prostate cancer. Three bombesin receptor subtypes, termed gastrin-releasing peptide receptor (GRPR), neuromedin B receptor (NMBR), and bombesin receptor subtype 3 (BRS-3), have been identified in rodents and humans. METHODS. We investigated the presence and characteristics of the functional receptors for bombesin/GRP in human prostate adenocarcinoma specimens by radio-receptor assay and the mRNA expression of the three bombesin receptor subtypes by RT-PCR. RESULTS. Of the 80 specimens of primary prostate cancer examined by receptor binding assays, 50 (~63%) showed high- affinity, low-capacity binding sites for bombesin/GRP, and 12 of these 50 receptor-positive specimens also showed a second binding site. Of the 22 prostate cancer specimens analyzed by RT-PCR, 20 (91%) expressed GRPR mRNA, 3 (14%) showed NMBR mRNA, and 2 (~9%) revealed BRS-3 mRNA. No correlation was observed between receptor expression and patients' age or pathological data. CONCLUSIONS. The detection of a wide distribution of bombesin/GRP receptors in human prostate carcinomas supports the view that they may be involved in modulation of tumor progression and suggests that approaches based on binding of bombesin receptor antagonists or new targeted cytotoxic bombesin analogs to prostate cancers could be considered for the therapy. (C) 2000 Wiley-Liss, Inc.

AB - BACKGROUND. Bombesin-like peptides can function as autocrine or paracrine growth factors and stimulate the growth of some cancer cells, including human prostate cancer. Three bombesin receptor subtypes, termed gastrin-releasing peptide receptor (GRPR), neuromedin B receptor (NMBR), and bombesin receptor subtype 3 (BRS-3), have been identified in rodents and humans. METHODS. We investigated the presence and characteristics of the functional receptors for bombesin/GRP in human prostate adenocarcinoma specimens by radio-receptor assay and the mRNA expression of the three bombesin receptor subtypes by RT-PCR. RESULTS. Of the 80 specimens of primary prostate cancer examined by receptor binding assays, 50 (~63%) showed high- affinity, low-capacity binding sites for bombesin/GRP, and 12 of these 50 receptor-positive specimens also showed a second binding site. Of the 22 prostate cancer specimens analyzed by RT-PCR, 20 (91%) expressed GRPR mRNA, 3 (14%) showed NMBR mRNA, and 2 (~9%) revealed BRS-3 mRNA. No correlation was observed between receptor expression and patients' age or pathological data. CONCLUSIONS. The detection of a wide distribution of bombesin/GRP receptors in human prostate carcinomas supports the view that they may be involved in modulation of tumor progression and suggests that approaches based on binding of bombesin receptor antagonists or new targeted cytotoxic bombesin analogs to prostate cancers could be considered for the therapy. (C) 2000 Wiley-Liss, Inc.

KW - Bombesin receptor

KW - Cancer therapy

KW - Peptide analogs

KW - Prostate cancer

KW - Receptor binding assay

KW - RT-PCR

UR - http://www.scopus.com/inward/record.url?scp=0033953894&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033953894&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-0045(20000301)42:4<295::AID-PROS7>3.0.CO;2-B

DO - 10.1002/(SICI)1097-0045(20000301)42:4<295::AID-PROS7>3.0.CO;2-B

M3 - Article

C2 - 10679759

AN - SCOPUS:0033953894

VL - 42

SP - 295

EP - 303

JO - Prostate

JF - Prostate

SN - 0270-4137

IS - 4

ER -